Ando Y, Kawaoka T, Suehiro Y, et al. - Researchers sought to report on the prognosis for patients with unresectable hepatocellular carcinoma (HCC) who exhibit disease progression after first-line lenvatinib (LEN) therapy. Among 141 patients with unresectable HCC, Child-Pugh class A liver function, and an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1, who received treatment with LEN from March 2018 to December 2019, 105 patients received LEN as first-line therapy, of whom, 53 had progressive disease (PD) at the radiological evaluation. Among patients with PD on first-line LEN, they observed important and favorable effect of good liver function at introduction of LEN on related eligibility for second-line therapy. In addition, improvement in prognosis was observed postprogression among patients who had been treated with first-line LEN in correlation with receiving treatment with molecular targeted agents.